Navigation Links
2 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma
Date:7/24/2011

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most susceptible to long-term damage.

Hodgkin's lymphoma is one of the most treatable cancers, with more than 90 percent of patients surviving after a combination of radiation and chemotherapy. But nearly 20 percent of patients treated as children develop a second cancer within 30 years. The younger the patients are when treated and the higher the radiation dose, the greater the risk. This late side effect of treatment is the second leading cause of death for long-term Hodgkin's survivors.

"This finding means we can better identify children who are most susceptible to radiation-induced cancers before treatment begins and modify their care to prevent this serious long-term complication," said Kenan Onel, MD, PhD, associate professor of pediatrics and senior author of the study. "Luckily our options for Hodgkin's are broad enough that we can find ways to control the initial disease without relying on radiation therapy."

"This is also a triumph for genome-wide association studies," he added. "Many previous GWAS studies found multiple genetic differences, with each of them playing only a modest role, with minimal impact on clinical management. In this study, which focused on the interaction between genes and a very specific environmental factorcancer long after radiation therapya small number of genetic differences produced a very big impact."

Onel and colleagues analyzed the genomes of 178 Hodgkin's patients who had been treated between the ages of 8 and 20 with chemotherapy and radiation therapy. Within 30 years after treatment, 96 of them had developed second cancers and 82 had not.

When they scanned each patient's genome, focusing on 665,313 tiny genetic variations known as single nucleotide polymorphisms, they found three variations that appeared far more often in patients with second cancers. When they repeated the study using a different set of patients62 cases with second cancers and 71 withouttwo of the three markers were significant.

Those two markers were both from a small region known as 21q on chromosome 6. Both are positioned near a gene known as PRDM1.

The genetic variations closely associated with increased cancer risk, and with each other, appeared to decrease activation of the PRMD1 gene. They had no detectable effect any other genes. Cells with the protective version of both markers expressed PRDM1 after being exposed to radiation. Cells with the variants linked to subsequent cancers did not produce any PRDM1.

Previous studies have found that PRDM1 is involved in a variety of fundamental cellular processes, including proliferation, differentiation and apoptosiswhich can all go awry in cancer. The gene's activity is lost in many cancer types.

In Onel's small samples, only three percent of patients with both of the protective variants developed second cancers within 30 years; nearly 33 percent of those with both of the high-risk variations did.

"Taken together," the authors note, "our findings support a novel role for PRDM1 as a radiation-responsive tumor suppressor." PRMD1 may be important for understanding the causes of second cancers in survivors of pediatric Hodgkin's lymphoma as well as in other cancer patients treated with radiation therapy."

This study should also "bring some optimism" back to genome-wide association studies, Onel added. Most previous cancer-related markers found through GWAS have been "of little clinical value for predicting risk, response to therapy or survival." But by incorporating environmental exposure, such as radiation therapy, into genomic investigations, "much of the missing heritability can be revealed," he said. "By folding in the environmental component, we were able to ask a more targeted question. This approach could improve our ability to integrate genomics into routine cancer care."


'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert  

Related biology news :

1. Epigenetic memory key to nature versus nurture
2. Life scientists use novel technique to produce genetic map for African Americans
3. Clinical tests for medicines made from genetically modified plants
4. Animal model sheds light on rare genetic disorder, signaling pathway
5. Genetic research confirms that non-Africans are part Neanderthal
6. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
7. Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death
8. New genetic map of potato may lead to improved crops
9. Genetic switch for limbs and digits found in ancient fish
10. New genetic clues for schizophrenia
11. Unlocking the genetics and biology of ankylosing spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... International, a not-for-profit organization focused on the ethics and governance ... to patients around the world, today announced that the editors ... the Good Pharma Scorecard an ,Editors, Pick, ... of BMJ Open ,s ,Most Popular Articles, which includes ... read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology: